Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.

Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.

Researchers at Ehime University, Hamamatsu University School of Medicine and Shizuoka University have disclosed compounds reported to be useful for the treatment of hepatitis C virus (HCV) infections.

Pfizer Inc. has described acetyltransferase KAT2A and/or KAT2B inhibitors reported to be useful for the treatment of cancer.

Cascade Pharmaceuticals Inc. has divulged free fatty acid receptor 1 (FFAR1; GPR40) agonists reported to be useful for the treatment of diabetes.

Kestrel Therapeutics Inc. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Euregen Biopharma Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.

Researchers at Semmelweis University and University of Szeged have disclosed aminoalkylated benzoxy compounds acting as potassium channel blockers reported to be useful for the treatment of atrial fibrillation and ventricular arrhythmia.

Mayo Foundation for Medical Education and Research (MFMER) has described glycogen synthase kinase 3 (GSK-3) inhibitors reported to be useful for the treatment of cancer, neurological and psychiatric disorders.

Scientists at GT Apeiron Therapeutics and Shanghai Apeiron Biotechnology Co. Ltd. have divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.